| Detected | Trial | Change |
|---|---|---|
| 2026-08-14 | NCT07562022 A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in… |
Recruitment opened |
| 2026-08-14 | NCT07570823 A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and… |
Recruitment opened |
| 2026-08-09 | NCT06197009 Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis |
overall status: Not Yet Recruiting → Unknown |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07362459 | A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in… | Non-Small Cell Lung Carcinoma (NSCLC) | Recruiting |
| NCT07297329 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib… | Multiple Myeloma (MM) | Recruiting |
| NCT07388602 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib… | Amyloidosis | Recruiting |
| NCT07437404 | Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A… | Haemophilia A | Recruiting |
| NCT07562022 | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in… | Follicular Lymphoma (FL) | Recruiting |
| NCT07570823 | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and… | DLBCL - Diffuse Large B Cell Lymphoma | Recruiting |
| NCT06041061 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women… | HPV InfectioN | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT07662395 | SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer | Double Blind | Recruiting |
| NCT04709328 | To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19 | COVID-19 | Not Yet Recruiting |
| Phase 2 | |||
| NCT07244510 | Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis… | Hidradenitis Suppurativa (HS) | Recruiting |
| NCT07609251 | A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated… | NSCLC (Advanced Non-small Cell Lung Cancer) | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT06600022 | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult… | Advanced Malignant Solid Tumours | Recruiting |
| NCT06754605 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant… | Respiratory Syncytial Virus | Recruiting |
| NCT06841042 | A Study of SCTB35 in Patients with Systemic Lupus Erythematosus | System Lupus Erythematosus | Recruiting |
| NCT07050641 | Phase I/II Study of SCTB39-1 in Advanced Solid Tumours | Advanced Malignant Solid Tumor | Recruiting |
| NCT06672536 | Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of… | nAMD | Recruiting |
| NCT06304818 | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult… | Advanced Malignant Solid Tumours | Not Yet Recruiting |
| NCT06769984 | A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease. | TED | Not Yet Recruiting |
| NCT06774664 | A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases | IgA Nephropathy | Not Yet Recruiting |
| NCT06801509 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes… | Herpes Zoster | Not Yet Recruiting |
| NCT07077252 | Phase I/II Study of SCTB39G in Advanced Solid Tumours | Advanced Malignant Solid Tumor | Not Yet Recruiting |
| NCT07538154 | A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus (SLE) | Not Yet Recruiting |
| NCT07594028 | Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced… | Advanced Malignant Solid Tumor | Not Yet Recruiting |
| NCT07665970 | SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors | Advanced Malignant Solid Tumors | Not Yet Recruiting |
| Phase 1 | |||
| NCT06252298 | A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies | Relapsed or Refractory Hematologic Malignancies | Recruiting |